<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03222440</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-RT-ESC-IIT</org_study_id>
    <nct_id>NCT03222440</nct_id>
  </id_info>
  <brief_title>Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC</brief_title>
  <official_title>A Single Arm Exploratory Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Locally Advanced Esophageal Squamous Cell Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an open-label，single
      center ，non-randomized ，Single Arm Exploratory Study . This clinical study is an
      investigator-initiatedclini-cal trial（IIT ）.The objective of this study is to evaluate the
      efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 in
      patients with Locally Advanced Esophageal Squamous Cell Carcinomas。
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 20, 2017</start_date>
  <completion_date type="Anticipated">July 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Through study completion, an average of half a year</time_frame>
    <description>Adverse events (AE), Serious Adverse Event(SAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1year and 3years</time_frame>
    <description>Progression-Free Survial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1year and 3years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-1210+ Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy,intensity modulated radiation therapy (IMRT), 54-60 Gy, 1.8-2.0 Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 9 cycles,one cycle is two weeks ) will be administered as an intravenous infusion over 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.</description>
    <arm_group_label>SHR-1210+ Radiotherapy</arm_group_label>
    <other_name>Anti-PD-1 Antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age:18-75 years, male or femal.

          2. Histologically confirmed primary Squamous Cell Carcinoma of the Esophagus,Local
             advanced esophageal cancer diagnosed by pathology and imaging,clinical stage T3-4N0M0,
             T1-4N+M0,Ⅱ-Ⅳa.

          3. Pre-treatment evaluation can not tolerate concurrent radiochemotherapy or rejection of
             the concurrent use of chemotherapy with radiotherapy.

          4. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

          5. ECOG 0-1.

          6. Adequate organ function.

          7. Life expectancy of greater than 6 months.

          8. Patient has given written informed consent.

        Exclusion Criteria:

          1. Patients who have or are currently undergoing additional chemotherapy, radiation
             therapy, targeted therapy or immunotherapy.

          2. Known history of hypersensitivity to macromolecular protein preparation or any
             components of the SHR- 1210 formulation.

          3. Subjects before or at the same time with other malignant tumors (except which has
             cured skin basal cell carcinoma and cervical carcinoma in situ);

          4. Subjects with any active autoimmune disease or history of autoimmune disease

          5. Uncontrolled clinically significant heart disease, including but not limited to the
             following: (1) &gt; NYHA II congestive heart failure; (2) unstable angina, (3) myocardial
             infarction within the past 1 year; (4) clinically significant supraventricular
             arrhythmia or ventricular arrhythmia requirement for treatment or intervention;

          6. Active infection or an unexplained fever &gt; 38.5°C during screening or before the first
             scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion
             of the investigator);

          7. Received a live vaccine within 4 weeks of the first dose of study medication.

          8. Pregnancy or breast feeding.

          9. Decision of unsuitableness by principal investigator or physician-in-charge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PING WANG, MD.PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PING WANG, MD.PHD</last_name>
    <phone>13032215357</phone>
    <email>wangping@tjmuch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Wang, M. D.</last_name>
      <phone>08623340123-1141</phone>
      <email>wangping@tjmuch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

